Drug
Neu 411
Neu 411: highest development phase Phase 2, developed by QIAGEN. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- QIAGEN
Trials
| Drug | Phase | Indication |
|---|---|---|
| NEU-411 NCT06680830 | Phase 2 | Parkinson Disease |
Latest
No recent events.
Follow Neu 411 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.